ERBB2 and lung carcinoma: For example, amplifications of EGFR in gliomas (98), MYCN in neuroblastoma (99), MYC in acute myeloid leukemia (100), and ERBB2 in breast (101), ovarian (102), and lung cancers (103) have been reported.